SRRA - シエラ・オンコロジ― (Sierra Oncology Inc.)

SRRAのニュース

   Sierra Oncology to Present at Three September Investor Conferences  2021/09/07 11:00:00 Business Wire
SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today announced the company will participate in three investor conferences in September 2021. Stephen Dilly, MBBS, PhD, President and Chief Executive Officer of Sierra Oncology will provide a company update at the HC Wainwright 23rd Annual Global Investment Conference and the Oppenheimer Fall Healthcare Life
   Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)  2021/09/03 20:05:00 Business Wire
SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, granted stock options to five new employees as approved by the Compensation Committee of the Companys Board of Directors, under Sierra Oncologys 2018 Equity Inducement Plan. The 2018 Equity Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to such individual
   Sierra Oncology accelerates planned filing of myelofibrosis candidate momelotinib  2021/08/09 12:08:29 Seeking Alpha
   Sierra Oncology Provides Update to Momelotinib Development Timeline and Closes on $34 Million in Additional Funding  2021/08/09 11:00:00 Business Wire
SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today updated guidance on the development timeline for its lead product candidate, momelotinib. The company now expects topline data from the Phase 3 registration-enabling MOMENTUM study by February 2022, and assuming positive results, the company plans to file a New Drug Application with the U.S. Food &
   Sierra Oncology Bets $216M On AstraZeneca''s BET Inhibitor For Myelofibrosis  2021/08/06 12:06:55 Benzinga
Sierra Oncology Inc (NASDAQ: SRRA ) has acquired an exclusive global license from AstraZeneca Plc (NASDAQ: AZN ) for AZD5153, a potent, and selective BRD4 BET inhibitor with a novel bivalent binding mode. Sierra plans to initiate a Phase 2 study evaluating momelotinib in combination with AZD5153 in myelofibrosis patients in 1H of 2022. Under the agreement terms, Full story available on Benzinga.com
   Karyopharm Therapeutics (NASDAQ:KPTI) versus Sierra Oncology (NASDAQ:SRRA) Head-To-Head Contrast  2020/10/24 23:00:43 Daily Political
Karyopharm Therapeutics (NASDAQ:KPTI) and Sierra Oncology (NASDAQ:SRRA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, dividends, analyst recommendations and profitability. Insider & Institutional Ownership 95.9% of Karyopharm Therapeutics shares are owned by institutional investors. Comparatively, […]
   Karyopharm Therapeutics (NASDAQ:KPTI) and Sierra Oncology (NASDAQ:SRRA) Critical Contrast  2020/10/22 20:14:46 US Banking News
Karyopharm Therapeutics (NASDAQ:KPTI) and Sierra Oncology (NASDAQ:SRRA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, valuation and institutional ownership. Insider & Institutional Ownership 95.9% of Karyopharm Therapeutics shares are owned by institutional investors. Comparatively, […]
   The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology  2020/02/11 12:23:06 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 10) AbbVie Inc (NYSE: ABBV ) Allergan plc (NYSE: AGN ) )(reacted to better-than-expected results and comments that its deal to be acquired by AbbVie is on track to close by the first quarter) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Aptose Biosciences Inc (NASDAQ: APTO ) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) Ascendis Pharma A/S (NASDAQ: ASND ) AtriCure Inc. (NASDAQ: ATRC ) ChemoCentryx Inc (NASDAQ: CCXI ) Co-Diagnostics Inc (NASDAQ: CODX )(announced sales of its new coronavirus test ) Cue Biopharma Inc (NASDAQ: CUE ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) DexCom, Inc. (NASDAQ: DXCM ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Fulgent Genetics Inc (NASDAQ: FLGT ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Insulet Corporation (NASDAQ: PODD ) Kodiak Sciences Inc (NASDAQ: KOD )(reacted to positive data readout from early-stage study of experimental drug to treat eye disorders) Masimo Corporation (NASDAQ: MASI ) Novartis AG (NYSE: NVS ) Pacira Biosciences Inc (NASDAQ: PCRX ) Principia Biopharma Inc (NASDAQ: PRNB ) PTC Therapeutics, Inc (NASDAQ: PTCT ) Revance Therapeutics Inc (NASDAQ: RVNC ) ResMed Inc.
   Sierra Oncology Completes Conversion of Preferred to Common Stock and Issues Stock to Gilead  2020/02/06 12:00:00 PR Newswire
/PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1,…
   Sierra Oncology : Shares Drop 12% Before Reverse Stock Split | MarketScreener  2020/01/22 18:08:02 MarketScreener
By Chris Wack Sierra Oncology shares dropped 12% to 34 cents after the company said its board of directors approved a reverse stock split of its shares at a ratio of 1-for-40, effective… | January 22, 2020

calendar